Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPEAT trial of single versus repeated intracoronary autologous bone marrow mononuclear cell therapy in chronic post-infarction heart failure
NL-OMON47617Phase 3Recruiting
- Sponsor
- Goethe University Frankfurt
- Start
- Feb 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of autologous bone marrow-derived mononuclear cell in heart failure (HF) and ischaemic cardiomyopathy (ICM) (2 arms), sponsored by Goethe University Frankfurt. Primary endpoint: 2-year total mortality. Started Feb 2016; status: recruiting.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
heart failure (HF)ischaemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NL-OMON47617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47617.